Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3045514 | 1.00 | KDM4E (0.41) | KDM4ELMNAFAAHCA1CA2 | |
| SCHEMBL3036850 | 0.77 | ALDH1A1 (0.43) | KDM4ELMNAHPGDKMT2AHCAR2 | |
| SCHEMBL3036997 | 0.77 | ALDH1A1 (0.43) | KDM4ELMNAHPGDKMT2AHCAR2 | |
| SCHEMBL3036957 | 0.77 | ALDH1A1 (0.43) | KDM4ELMNAHPGDKMT2AHCAR2 | |
| Propofol SCHEMBL28405985 | 0.74 | GABRA1 (0.68) | KDM4ELMNAFAAHCA1CA2 | |
| SCHEMBL13465453 | 0.74 | GABRA1 (0.43) | LMNAFAAHCA1CA2CYP1A2 | |
| SCHEMBL4023092 | 0.72 | SCN5A (0.49) | — | |
| SCHEMBL1952758 | 0.70 | SCN5A (0.58) | LMNAFAAHCA1CA2CYP1A2 | |
| Chloromethane SCHEMBL28360619 | 0.69 | SCN5A (0.47) | — | |
| SCHEMBL1927023 | 0.68 | SCN5A (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | claimed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | claimed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | claimed |
| US-8470861-B2 | Mitochondria-targeted antioxidant prodrugs and methods of use | UNIVERSITY OF ROCHESTER (US) | 2013-06-25 | — | — | US | claimed |
| US-12377110-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4288062-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | Epalex Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230277567-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-09-07 | — | — | US | disclosed |
| US-11628178-B2 | Fospropofol methods and compositions | EPALEX CORPORATION (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230084521-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2023-03-16 | — | — | US | disclosed |
| US-20220265686-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-08-25 | — | — | US | disclosed |
| US-20220105050-A1 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | EPALEX CORPORATION | 2022-04-07 | — | — | US | disclosed |
| US-8470861-B2 | Mitochondria-targeted antioxidant prodrugs and methods of use | UNIVERSITY OF ROCHESTER (US) | 2013-06-25 | — | — | US | disclosed |
| US-20100168198-A1 | Mitochondria-targeted antioxidant prodrugs and methods of use | UNIVERSITY OF ROCHESTER | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11628178-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | KDM4E 3149/4885LMNA 2765/4885FAAH 88/4885 |
| US-20100168198-A1 | Mitochondria-targeted antioxidant prodrugs and methods of use | TXNRD2, HADHA, PRDX5 | KDM4E 3075/4885LMNA 2194/4885FAAH 375/4885 |
| US-20230277567-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | KDM4E 3149/4885LMNA 2765/4885FAAH 88/4885 |
| US-12377110-B2 | Fospropofol methods and compositions | FOS, FOSB, PFAS | KDM4E 3149/4885LMNA 2765/4885FAAH 88/4885 |
| US-20220265686-A1 | FOSPROPOFOL METHODS AND COMPOSITIONS | FOS, FOSB, PFAS | KDM4E 3149/4885LMNA 2765/4885FAAH 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.